Home › cancer
 

Keywords :   


Tag: cancer

Bayer And Orion Collaborate To Develop Prostate Cancer Drug

2014-06-04 18:52:33| Chemicals - Topix.net

Bayer and Orion announced that the companies have entered into a global partnership to develop and commercialize the investigational compound ODM-201 for the treatment of patients with prostate cancer.

Tags: develop drug cancer bayer

 

Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer

2014-06-04 12:52:32| drugdiscoveryonline News Articles

Novogen Limited (NASDAQ: NVGN, ASX:NRT), an oncology drug development company, today announced that it has achieved a key milestone with its super-benzopyran (SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro

Tags: active highly drug cancer

 
 

Cancer Centers Combine Expertise To Optimize Advanced Immunotherapy Strategies

2014-06-04 12:44:04| drugdiscoveryonline News Articles

Physician researchers from Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center (JTCC) in Hackensack, New Jersey, announce today the formation of the Regional Immunotherapy Discovery Program

Tags: advanced cancer strategies centers

 

Cancer Survivor From Reading Wins Makeover Contest

2014-06-03 20:31:46| Apparel - Topix.net

Friends of Joyce Kellette's submitted her photo for a makeover contest, but honestly "never thought she'd win."

Tags: reading cancer contest wins

 

First Presentation of Data for Pembrolizumab, Mercks Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014

2014-06-02 13:30:00| Merck.com - Corporate News

Dateline City: CHICAGO Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024) Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Mercks Proprietary PD-L1 Assay at One Percent and 50 Percent Cut Points CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data advanced cell presentation

 

Sites : [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] next »